Title (en)

NOVEL 1,2,5-TRISUBSTITUTED 1,2-DIHYDRO-INDAZOL-3-ONES WITH ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY, IMMUNO-MODULATING AND NEURO-PROTECTIVE EFFECT, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT

Title (de)

NEUE 1,2,5-TRISUBSTITUIERTE 1,2-DIHYDRO-INDAZOL-3-ONE MIT ANTIASTHMATISCHER, ANTIALLERGISCHER, ENTZÜNDUNGSHEMMENDER, IMMUNMODULIERENDER UND NEUROPROTEKTIVER WIRKUNG, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL

Title (fr)

NOUVELLES 1,2-DIHYDRO-INDAZOL-3-ONES TRISUBSTITUEES AUX POSITIONS 1,2,5, A EFFET ANTI-ASTHMATIQUE, ANTI-ALLERGIQUE, ANTI-INFLAMMATOIRE, IMMUNOMODULATEUR ET NEUROPROTECTEUR, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION COMME MEDICAMENT

Publication

**EP 1077948 A1 20010228 (DE)**

Application

**EP 99950343 A 19990401**

Priority

- DE 19821003 A 19980511
- EP 9902291 W 19990401

Abstract (en)

[origin: US6180637B1] The invention relates to 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones of formula (I)whereinX is -SO2-, -SO-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Y is -(C=O)-, -(C=O)-NH-, -(C=O)-NH-(CH2)p-, -C=O)-(CH2)p-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-(C=O)-NH-(CH2)p-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Z is -O-, -O-(CH2)p-, -NH-, -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-CH2-(C=O)- and -NH-(C=O)-CH2-,P is a cardinal number from 1 to 4,R1, R2 and R3 can be the same or different and are:mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 5 to 14 ring members; or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,in which the carbocycles and the heterocycles can be mono- or polysubstituted by:C1-6-alkyl, -O-C1-6-alkyl, -O-C3-7-cycloalkyl, mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 3 to 14 ring members, mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,R1 is also H, provided that when X is CH2, then R1 is not H,R3-Z is also NO2,and their pharmaceutically acceptable salts,but excluding compounds of formula (I) in whichif Z is -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-(C=O)-CH2 and at the same time R1 is phenyl, monosubstituted or polysubstituted by -COOH, -COOC1-6-alkyl, -(CH2)p-COOH, -(CH2)p-COOC1-6-alkyl -CONHC1-6-alkyl, -CONHC6-14-aryl, -CONHSO2C1-6-alkyl, -CONHSO2C6-4-aryl, 1H-tetrazol-5-yl, then R2 is not phenyl, monosubstituted or polysubstituted by CN, halogen, C1-4-alkyl, C1-4-alkyloxy, CF3; andif R3-Z is NO2, then R1-X is not benzyl or 4-methoxybenzyl, and R2-Y is not benzyl or 2-picolyl at the same time; and to pharmaceutical treatment processes, and processes for making.

IPC 1-7

**C07D 231/56**; C07D 417/06; C07D 403/06; A61K 31/415; A61K 31/425; A61K 31/495

IPC 8 full level

**A61K 9/02** (2006.01); **A61K 9/08** (2006.01); **A61K 9/12** (2006.01); **A61K 9/14** (2006.01); **A61K 9/20** (2006.01); **A61K 9/28** (2006.01); **A61K 9/48** (2006.01); **A61K 9/70** (2006.01); **A61K 31/416** (2006.01); **A61K 31/417** (2006.01); **A61K 31/427** (2006.01); **A61K 31/496** (2006.01); **A61K 31/506** (2006.01); **A61K 31/517** (2006.01); **A61P 11/06** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07D 231/56** (2006.01); **C07D 403/06** (2006.01); **C07D 417/06** (2006.01)

CPC (source: EP KR US)

**A61P 11/06** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/16** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 231/56** (2013.01 - EP KR US); **C07D 235/26** (2013.01 - KR); **C07D 277/22** (2013.01 - KR); **C07D 295/135** (2013.01 - KR); **C07D 401/06** (2013.01 - KR); **C07D 403/06** (2013.01 - EP US); **C07D 417/06** (2013.01 - EP KR US)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**US 6180637 B1 20010130**; AR 018605 A1 20011128; AU 4257699 A 19991129; AU 745796 B2 20020328; BG 104910 A 20010629; BR 9911772 A 20010206; CA 2271837 A1 19991111; CN 1309642 A 20010822; CO 5021131 A1 20010327; DE 19821003 A1 19991118; EP 1077948 A1 20010228; HK 1038751 A1 20020328; HU P0101707 A2 20020328; HU P0101707 A3 20020628; IL 139358 A0 20011125; JP 2002514627 A 20020521; KR 20010025011 A 20010326; NO 20005698 D0 20001110; NO 20005698 L 20010108; NZ 508646 A 20021126; PL 344254 A1 20011022; SK 17082000 A3 20010911; TR 200003302 T2 20010221; TW 448163 B 20010801; WO 9958504 A1 19991118; WO 9958504 A9 20000203; ZA 200006151 B 20001206

DOCDB simple family (application)

**US 30560299 A 19990505**; AR P990102212 A 19990511; AU 4257699 A 19990401; BG 10491000 A 20001103; BR 9911772 A 19990401; CA 2271837 A 19990511; CN 99808515 A 19990401; CO 99028290 A 19990507; DE 19821003 A 19980511; EP 9902291 W 19990401; EP 99950343 A 19990401; HK 02100376 A 20020117; HU P0101707 A 19990401; IL 13935899 A 19990401; JP 2000548308 A 19990401; KR 20007012614 A 20001110; NO 20005698 A 20001110; NZ 50864699 A 19990401; PL 34425499 A 19990401; SK 17082000 A 19990401; TR 200003302 T 19990401; TW 88106565 A 19990423; ZA 200006151 A 20001031